Bevacizumab Price in India: — Innovator, Biosimilar and Cost Per Cycle

No. A generic is a chemically identical copy of a small-molecule drug. Bevacizumab is a large, complex biologic produced in living cells, and no two batches are molecularly identical. A biosimilar is a separately manufactured product that has passed rigorous comparability testing and received CDSCO approval because it is highly similar in structure, function and clinical effect. That approval process is what distinguishes a CDSCO-approved biosimilar from an unapproved copy.

Bevacizumab is listed under Pradhan Mantri Jan Arogya Yojana for eligible patients in certain cancer diagnoses, though coverage depends on your specific diagnosis, treatment setting, and state. Private insurance policies vary widely: some cover oncology day-care infusions and others exclude specific drugs or require pre-authorisation. Ask the hospital's insurance desk before your first cycle — they process these claims regularly and can tell you quickly whether yours is likely to be approved and what documentation you will need.

The number of cycles depends on your cancer type, your response to treatment, and the protocol your oncologist is following. Bevacizumab is often given alongside chemotherapy and may continue as maintenance in some settings. Ask your oncologist at your next appointment how many cycles are currently planned and at what point your response will be reassessed — usually with imaging. That gives you both a timeline and a basis for estimating total cost from your per-cycle figure.

ASCO and ESMO guidance does not support that position. Both bodies recognise CDSCO-approved biosimilars as appropriate alternatives to the reference product in suitable clinical settings. The CDSCO approval process requires the manufacturer to demonstrate that their product is clinically comparable to the innovator. The choice at your centre is almost always a procurement and supply decision. If you have concerns, ask your oncologist directly — they should be able to explain the basis for their centre's choice.

Some patients do switch mid-treatment. ASCO acknowledges that switching to an approved biosimilar during a course of treatment is a clinical decision to be made by the oncologist in discussion with the patient — not something to arrange independently or request solely on grounds of cost without discussion. If cost is creating pressure for your family, tell your oncologist directly. Your centre may already be using a biosimilar, or they may be able to assess whether a switch is appropriate in your case.

Hospitals procure medicines through different channels and at different volumes, and they add their own pharmacy margins and service charges on top of the procurement price. A government hospital, a cancer trust, a private oncology centre and a corporate hospital will all quote differently for the same vial. The figures in this guide represent indicative market ranges as of mid-2025. Your actual bill reflects your centre's specific pricing. Ask for a written cost estimate before your first infusion so there are no surprises at billing.